Endothelial progenitor cells for pulmonary hypertension

The purpose of this study is to assess the feasibility, safety, and initial clinical outcome of intravenous infusion of autologous endothelial progenitor cells (EPCs) to patients with pulmonary hypertension. So far, treatment has been well tolerated. Importantly, the pulmonary resistance did not show any increase after treatment, rather, there appeared to be a substantial decrease over the 3 days of cell delivery. There was also an improvement in 6-minute walk distance. After a period of three months, this improvement declined back to the original state, indicating that treatment would likely need to be repeated over time.